actuatetherapeutics.com - ACTU Aggregate Business Value
The price trajectory of Actuate Therapeutics, Inc. (ACTU) reflects a scenario where the company is depleting reserves on clinical trials without current sales, while the Enterprise Value stands at 4.02. The business relies on alliances with oncology centers to accelerate the launch of elraglisib. Growth potential is based on patents, as the commercialization of new drugs will ensure a sharp surge in revenue with low production costs.
Summary analytical data breakdowns for Actuate Therapeutics, Inc. (ACTU)
The enterprise value of Actuate Therapeutics, Inc. (ACTU) at 4.02 reflects the total cost of business acquisition, combining market capitalization and debt load minus liquid assets. By analyzing historical EV levels, an investor assesses the fundamental stability of this biopharmaceutical startup developing innovative GSK-3 beta inhibitors to combat resistant forms of oncology.